

Supplementary Table S7. Univariate and multivariate analyses for progression free survival and overall survival.

CA125, cancer antigen 125; ULN, upper limit of the normal range; HR, hazard ratio; CI, confidence interval. FIGO stage I, II or III, IV were assigned to the early and advanced groups, respectively. Cases with B7-H3 IHC scores of 0/1 or 2/3 were assigned to the low and high groups, respectively. Cases with CD206+ M2 macrophage numbers < or ≥ the median value were assigned to the sparse and rich groups, respectively. *Statistical significance.

Variables	n		Progression free survival				Overall survival			
			Univariate		Multivariate		Univariate		Multivariate	
			HR (95% CI)	<i>P</i> value	HR (95% CI)	<i>P</i> value	HR (95% CI)	<i>P</i> value	HR (95% CI)	<i>P</i> value
Age ≥ 65	< 65	45	1.05 (0.50-2.22)	0.89	1.16 (0.48-2.78)	0.75	1.19 (0.51-2.75)	0.69	1.36 (0.55-3.37)	0.50
	≥ 65	17								
Advanced FIGO stage	I, II	11	5.27 (1.26-22.1)	0.02*	4.70 (0.83-26.8)	0.08	7.11 (0.96-52.5)	0.055	4.43 (0.50-39.5)	0.18
	III, IV	51								
High level of CA125	≤ ULN	7	1.67 (0.51-5.49)	0.40	0.84 (0.20-3.55)	0.81	3.59 (0.49-26.5)	0.21	2.31 (0.27-20.1)	0.45
	> ULN	55								
Residual tumor at initial debulking surgery	No	32	2.22 (1.10-4.48)	0.03*	1.28 (0.58-2.82)	0.54	1.85 (0.84-4.09)	0.13	1.10 (0.46-2.64)	0.83
	Yes	30								
B7-H3 expression high	Low	31	2.09 (1.04-4.21)	0.04*	1.97 (0.92-4.23)	0.08	2.42 (1.08-5.44)	0.03*	2.30 (0.99-5.38)	0.054
	High	31								
M2 macrophage rich	Sparse	30	1.32 (0.67-2.62)	0.43	1.22 (0.60-2.48)	0.58	1.17 (0.54-2.52)	0.70	1.13 (0.51-2.49)	0.76
	Rich	32								